The Parsemus Foundation and Revolution Contraceptives LLC are pleased to announce that NEXT Life Sciences, Inc. has been selected to continue development of the Vasalgel male contraceptive.
After a decade of research on Vasalgel, the Parsemus Foundation and its social venture spinoff Revolution Contraceptives LLC determined that the reversible, long-lasting male contraceptive was ready to advance to the next level. The search began for an organization with the resources needed to lead the project through the next steps to the marketplace, including clinical trials and regulatory review. Elaine Lissner, founder and trustee of the Parsemus Foundation and lifelong advocate for male contraception, announced today the selection of NEXT Life Sciences, Inc. as that partner.
NEXT Life Sciences’ mission is to develop and distribute medical technology that empowers people to choose when and whether to have a child. Founder and CEO L.R. Fox, a successful entrepreneur with a deep commitment to reproductive equality, has been recognized by Forbes “30 Under 30” as one of the brightest young leaders changing the world.
In addition to NEXT Life Sciences’ having the organizational and financial resources to successfully move Vasalgel to market, Fox and Lissner are aligned on the social mission of Vasalgel, a crucial element to the partnership. Ensuring that the product is widely available and affordable is built into Vasalgel’s development plan.
Read the NEXT Life Sciences press release here.
To stay informed about Vasalgel’s progress and learn more about NEXT Life Sciences, go to nextlifesciences.org and click “Join the Movement.“